loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Masofaniten

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Masofaniten

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ESSA Pharma Reports Q3 2024 Financial Results And Updates
    ESSA Pharma Reports Q3 2024 Financial Results And Updates

    05 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quarter-ended-june-30-2024-302213920.html

    PR NEWSWIRE
    05 Aug 2024
    Share Share
    ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
    ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data

    25 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-presents-updated-phase-1-masofaniten-epi-7386-clinical-data-at-the-2024-asco-genitourinary-cancers-symposium-302044194.html

    PR NEWSWIRE
    25 Jan 2024
    Share Share
    ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
    ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data

    21 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-presents-updated-phase-1-masofaniten-epi-7386-clinical-data-at-the-european-society-of-medical-oncology-2023-congress-301963689.html

    PR NEWSWIRE
    21 Oct 2023
    Share Share
    ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten
    ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten

    18 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-announces-initiation-of-phase-2-study-evaluating-masofaniten-epi-7386-in-combination-with-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-301929954.html

    PR NEWSWIRE
    18 Sep 2023
    Share Share